Business Context and Reporting Period
Company: Global Medical REIT Inc. (GMRE)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: An internally managed REIT that acquires healthcare facilities and leases them to physician groups and healthcare systems. The company operates as a single reportable segment.
Key Corporate Action: Completed a 1-for-5 reverse stock split on September 19, 2025. All share and per-share data in this summary are adjusted to reflect this split.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $37,229 | $34,264 | $109,816 | $103,624 |
| Net (Loss) Income | $(5,058) | $3,391 | $(736) | $3,753 |
| Net (Loss) Income Attributable to Common Stockholders | $(6,001) | $1,791 | $(4,698) | $(563) |
| Diluted EPS (Common) | $(0.45) | $0.14 | $(0.35) | $(0.04) |
| FFO (Common & NCI) | $14,530 | $13,731 | $43,570 | $42,558 |
| AFFO (Common & NCI) | $16,242 | $15,345 | $48,857 | $47,586 |
| Operating Cash Flow (9M) | $51,977 (2025) vs $49,523 (2024) | |||
| Total Debt (Net) | $709,635 (Sep 30, 2025) vs $646,131 (Dec 31, 2024) | |||
| Cash & Restricted Cash | $9,840 (Sep 30, 2025) vs $8,942 (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 8.6% year-over-year for the nine months ended September 30, 2025, driven by acquisitions completed in 2025, partially offset by dispositions.
- Net Loss: The company reported a net loss of $0.7 million for the nine months ended September 30, 2025, compared to net income of $3.8 million in the prior year period. This decline was primarily due to a $6.3 million impairment loss on the Aurora, Illinois facility and increased interest expense.
- Impairment: Recognized a $6.3 million impairment loss in Q3 2025 related to the Aurora, IL facility prior to its sale. No impairment was recorded in the comparable 2024 period.
- Interest Expense: Increased 10.6% for the nine months ended September 30, 2025, due to higher average borrowings and elevated interest rates (weighted average rate of 4.00% vs 3.93% in 2024).
- Dividend Reduction: The quarterly common stock dividend was reduced from $1.05 to $0.75 per share (split-adjusted) effective Q2 2025.
Guidance, Outlook, and Risks
- Debt Refinancing: On October 8, 2025 (subsequent to period end), the company amended its credit facility, extending the revolver maturity to 2029 and restructuring Term Loan A into three tranches maturing between 2029 and 2031. This removed a 10 basis point SOFR spread adjustment.
- Interest Rate Risk: While current rates have trended lower, the company notes that new interest rate swaps effective May 2026 will fix rates higher than current levels (3.24%–3.32% vs. 1.36% previously), which is expected to increase interest expense and negatively impact net income starting in 2026.
- Liquidity: The company maintains $171 million in unutilized borrowing capacity under its revolver as of November 3, 2025. Management believes cash flow from operations and the credit facility are sufficient to meet liquidity needs.
- Strategic Outlook: Management cites an aging population and a shift to outpatient care as positive trends. However, elevated interest rates and healthcare wage inflation remain headwinds affecting acquisition activity and tenant costs.
- Stock Repurchase: A $50 million stock repurchase program was approved in August 2025; no shares were repurchased during the quarter.
Investor Verification Checklist
- Impairment Details: Verify the specific valuation methodology and future cash flow assumptions used for the $6.3 million impairment on the Aurora, IL facility.
- Debt Maturity Profile: Review the impact of the October 2025 credit facility amendment on the weighted average cost of debt and maturity schedule, specifically the transition to higher fixed rates in 2026.
- Dividend Coverage: Assess the sustainability of the reduced $0.75 quarterly dividend against the reported AFFO of $3.37 per share for the nine-month period.
- Acquisition Pipeline: Evaluate the company's ability to deploy capital given the elevated cost of capital and the $171 million revolver capacity.
- Reverse Stock Split Impact: Confirm that all historical financial data presented in future filings is consistently adjusted for the 1-for-5 reverse split.